June 14, 2022
Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.
June 03, 2022
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
June 03, 2022
Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.
May 11, 2022
Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.
May 04, 2022
The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.
April 25, 2022
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
March 07, 2022
In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.
January 18, 2022
Bimekizumab, an interleukin 17A (IL-17A) and IL-17F inhibitor, met both primary and secondary endpoints for treating adult patients with non-radiographic axial spondyloarthritis.
December 02, 2021
“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.
October 08, 2021
Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.